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LIM proteins constitute a superfamily characterized by the presence of a LIM domain,
known to be involved in protein–protein interactions. Our previous work has implicated
members of the Zyxin family of LIM proteins, namely TRIP6 and LPP, in the repression of
the DNA damage response (DDR) at telomeres. Here, we describe a role for Ajuba, a closely
related LIM molecule, in repressing the ATR-mediated DDR. We found that depletion of
Ajuba led to apparent delays in the cell cycle, accompanied with increased Rb phosphorylation, Chk1 phosphorylation, induction of p53, and cell death. Ajuba could be found in
a complex with replication protein A (RPA), and its depletion led to RPA phosphorylation,
known to be an early event in ATR activation. We propose that Ajuba protects against
unscheduled ATR signaling by preventing inappropriate RPA phosphorylation.
Keywords: LIM protein, Ajuba, ATR, DNA damage, RPA

INTRODUCTION
Maintenance of genomic integrity is essential for accurate transmission of genetic information and cell viability. DNA damage by
endogenous and exogenous agents can lead to genomic instability,
itself a causative factor in early human tumorigenesis (Bartkova
et al., 2005; Gorgoulis et al., 2005). Cells have specific checkpoints to detect damaged or abnormally structured DNA and
allow for activation of repair mechanisms, or activation of apoptosis (reviewed in Ciccia and Elledge, 2010). Checkpoints operate
at distinct points in the cell cycle to check for DNA lesions and act
to delay transitions from both G1 to S phase and G2 to M phase, as
well as within S (reviewed in Zhou and Bartek, 2004). In addition,
checkpoints can monitor cells for M phase exit. In order to counteract and repair the DNA damage, the cell elicits a DNA damage
response (DDR), under the control of signaling kinases part of the
PIKK family, ATM, ATR, and DNA-PK (Ciccia and Elledge, 2010).
These DDRs are organized pathways consisting of specific steps of
damage sensing, transduction of a damage signal, and induction
and recruitment of repair proteins to the damaged sites. Of those,
ATM is important for the repair of double strand breaks and is
not essential for viability, but controls an important tumor suppressor pathway. ATR however, is essential, and is activated upon
types of damage generated by UV irradiation, such as Thymine
dimers, or DNA replication defects in S phase such as replication
fork collapses or accumulation of single stranded DNA. It has been
proposed that the essential nature of the ATR pathway is caused
by the necessity to repair spontaneous damage occurring during a
normal S phase, which would lead to an intolerable level of damage if left unrepaired (see Hurley and Bunz, 2007 and references
therein).
Abbreviations: ATM, ataxia-telangiectasia mutated; ATR, ataxia-telangiectasia and
Rad3-related; Chk1, Checkpoint 1; Chk2, Checkpoint 2; DDR, DNA damage
response; FACS, fluorescence activated cell sorting; LIM, Lin-1, Isl-1, Mec-3 domain;
RPA, replication protein A.
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The ATM and ATR kinases have a number of target substrates,
among which the kinases Chk1 and Chk2, which are important for
the respective cellular responses to the damage. Chk2 is an ATM
target and is phosphorylated after ionizing radiation. Chk1, on the
other hand, is a direct target of ATR, and is phosphorylated during
replication stress or UV irradiation. ATR, therefore, is the kinase
involved in responding to endogenous lesions or errors occurring
through the action of replication forks during a normal S phase
(Sorensen et al., 2004; Vassin et al., 2009).
During DNA replication, the single stranded DNA produced
is bound by replication protein A (RPA), a complex of three subunits, RPA70, RPA32, and RPA14, which binds single DNA through
OB fold structural motifs in a sequence-independent manner
(Wold, 1997). RPA is a central molecule in the activation of ATR.
The RPA32 subunit is phosphorylated after damage, and recruits
ATRIP, itself required for the activation process (Zou and Elledge,
2003). Upon a sustained DDR, the ATM pathway is activated leading to activation of p53 and further checkpoint delays in the cell
cycle.
Another event that can trigger DDR is telomere deprotection.
Mammalian telomeres consist of TTAGGG tandem repeats that
end with a 30 overhang (Palm and de Lange, 2008). A six-protein
complex called shelterin binds to the telomeric repeats, and, as part
of this complex, TRF2 was found to prevent inappropriate activation of ATM (Karlseder et al., 2004). Another shelterin protein,
POT1, directly binds the telomeric single stranded overhang and
protects against ATR activation (Lazzerini Denchi and de Lange,
2007; Palm et al., 2009).
Our laboratory has previously shown that members of a distinctive class of molecules called LIM proteins are implicated in
telomere protection by repressing DDR at telomeres (Sheppard
and Loayza, 2010; Sheppard et al., 2011). Specifically, LIM proteins TRIP6 and LPP belong to the Zyxin family (Kadrmas and
Beckerle, 2004) and interact with the shelterin complex to prevent
DDR activation at telomeres. The Zyxin family is characterized by
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the presence of three LIM domains present at the C-terminus, with
each domain containing of two Zinc fingers, and a unique pre-LIM
region at the N-terminus. They also posses a nuclear export signal close to the N-terminus and hence can shuttle between the
nucleus and the cytoplasm (Wang and Gilmore, 2001). The LIM
protein TRIP6, in particular, was shown to interact with OB-foldcontaining protein POT1 through the C-terminal LIM domains
(Sheppard and Loayza, 2010).
Here, we are investigating the role of Ajuba, a closely related
LIM protein, part of the Zyxin family. We found that Ajuba also
participates in the repression of the DDR, but in a genome-wide
fashion. We describe the role of Ajuba as a repressor of the ATR
pathway, and show that this molecule is in a complex with RPA
and prevents unscheduled phosphorylation of RPA32. We propose a model in which Ajuba controls the transition between local
activation of ATR during a normal S phase and the global ATR
activation occurring after extensive DNA damage.

MATERIALS AND METHODS
CELL LINES AND ANTIBODIES

The cell lines used were HTC75 cells and IMR90. The HTC75
cell line is a HT1080 derivative described in (van Steensel and
de Lange, 1997). IMR90 cells were obtained from the ATCC
at population doubling 21. The cells were grown in DMEM
supplemented with 1% penicillin and streptomycin, 10% BCS
for HTC75, and 10% FBS for IMR90 cells. The Ajuba antibody was obtained from Abcam (AB64451). The Ajuba serum
was generated against a peptide conjugated to KLH and used
for immunization into rabbits, as per the protocol set by the
manufacturer (BioSynthesis, Lewisville, TX, USA). The peptide
was: NH2-CPRGATGGPGDEPLEPAREQGSLDA-OH for Ajuba.
The antibodies for Rb-pS807/811(9308), PARP (9542), p53-pSer20 (9287), Cyclin A2 (4656), Chk1-p-S345 (2348), Chk1-pS296 (2349) were obtained from Cell signaling. The total Chk1
antibody was purchased from Sigma-Aldrich (C9358). The p53
antibody was acquired from Millipore (04-1083). The RPA-p-T21
antibody was purchased from Abcam (AB109394). The GAPDH
antibody was obtained from Santa Cruz (sc-32233). The p53BP1
(NB100-304) and RPA2 (9A1) antibody was purchased from
Novus.
DEPLETION BY siRNA

HTC75 cells and IMR90 cells were maintained in DMEM (Invitrogen)/1% penicillin and streptomycin/10% FBS. Ajuba specific siRNAs were synthesized by Dharmacon RNA Technologies. For Ajuba RNAi, double-stranded siRNA were designed
to target the following sequences: Ajuba si#1 siRNA 50 CCAAAUGGAUUGUGGAAGAUU-30 , Ajuba si#2 siRNA 50 GGGAAAGAGGUCAGAUUUAUU-30 , and Ajuba si#3 siRNA 50 GCAGCUGAGUGAUGAGGAAUU-30 . The cells were transfected
using Lipofectamine (Invitrogen) according to the manufacturer’s
instructions. Cells were grown to confluency of approximately
20–25% in a six-well plate 18–24 h prior to transfection. Transfections were done twice, once within a 24 h interval and another at
48 h. The cells were processed 72 h after the first transfection. As a
control, siRNA designed to target GFP (Dharmacon) was used.
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IMMUNOFLUORESCENCE

Immunostaining for p53BP1 performed on cells plated onto
glass coverslips and processed for RNAi. After the transfection
period, cells were washed twice with PBS, the cells were then fixed
with PBS/3% paraformaldehyde for 10 min at RT. After two PBS
washes, cells were permeabilized with PBS/0.5% NP40 and later
blocked with PBG [PBS/0.2% fish gelatin. 0.5% bovine serum
albumin (BSA)] for 30 min. Coverslips were then incubated with
the rabbit anti-p53BP1 antibody (Novus NB100-304A-1), at a
concentration of 1:500 in PBG overnight. Cover slips were then
rinsed three times with PBG solution and incubated with secondary TRITC-conjugated goat anti-rabbit antibody (Jackson
Immunoresearch) in PBG at a concentration of 1:500 for 45 min
at RT. Cover slips were rinsed two times with PBG. Coverslips
were then incubated with PBG and 4,6-diamidino-2-phenylindole
(DAPI) at 100 ng/mL to visualize the nuclei. Coverslips were
mounted on to slides with embedding media. Images were collected with an Olympus BX61 fluorescence microscope using a
60× objective connected to a Hamamatsu ORCA-ER CCD camera,
controlled by the SlideBook 5.1 image capture software.
CELL CYCLE ANALYSIS BY FACS

The cells were collected and rinsed twice in cold PBS/2 mM EDTA,
resuspended in 7 mL of PBS/2 mM EDTA/2% BSA, 3 mL of cold
100% Ethanol was added drop wise and the cells were kept at 4˚C
for 24 h fixation. The cells were then spun down and resuspended
in 0.5 mL of PBS/2 mM EDTA. Ten microliters of heat inactivated
RNase A (10 mg/mL) and 25 µl of Propidium Iodide (1 mg/mL)
were added and the cells were incubated at 37˚C for 30 min. The
samples were then analyzed using a FACS Calibur Flow Cytometer.
CO-IMMUNOPRECIPITATIONS

The immunoprecipitations were performed as described in
(Loayza and de Lange, 2003).

RESULTS
DEPLETION OF AJUBA BY siRNA LEADS TO S-PHASE DELAY IN HTC75
CELLS

We performed siRNA depletion of Ajuba in HTC75 cells using
three different target sites. The most effective depletion was
observed by Western blot with siRNA #3 (Figure 1C). In all three
cases, a significant reduction in total cell count was observed, down
to approximately 50% of viable cells compared to the GFP siRNA
control (Figures 1A,B), at 72 h after transfection. We then sought
to determine whether the cells at this time point showed a specific
alteration in their cell cycle profile. To this end, cells were fixed,
stained with propidium iodine and processed for FACS analysis
for DNA content. In all three cultures treated with Ajuba siRNA,
cells exhibited a significant increase in their number in S phase:
respectively 42.3, 44.9, and 46.5% in S phase in cells treated with
siRNA #1,2, or 3, compared with 24.95% in the GFP siRNA control (Figure 2A). An average of three experiments solidified this
observation, with siRNA #3 having the strongest effect, with 38%
of cells in S phase versus 25.1% of the cells in the control siRNA
(Figure 2C). We noted also a slight but reproducible increase in the
number of cells in G2/M with siRNA #3: 17.5% versus 12.4% of the
cells in the GFP siRNA control. There was also a notable increase
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FIGURE 1 | Depletion of Ajuba in HTC75 cells results in reduced cell
number. (A) Quantitation of three independent siRNA experiments
with cell counts performed at 72 h after the first transfection. (B) Cells

in cells with sub-G1 DNA content in all three siRNA depletions
compared to controls (Figure 2A). We concluded that depletion
of Ajuba led to a delay in S phase, possibly due to checkpoint activation. Protein extracts were prepared from these cells in order to
probe the molecular effects of Ajuba depletion. Given the cell cycle
profile observed, we were particularly interested in markers characteristic of this particular phase of the cell cycle. We found that,
in the viable cells, Rb was hyperphosphorylated (Figure 2B), compatible with the cells having passed the G1/S transition. Cyclin
A2 was also found at high levels (Figure 2B), a feature of cells
undergoing DNA replication.
DEPLETION OF AJUBA RESULTS IN ATR ACTIVATION FOLLOWED BY
APOPTOSIS IN HTC75 CELLS

The delay of cells in S phase prompted us to assess the level of
endogenous DNA damage in cells depleted for Ajuba. To that end,

www.frontiersin.org
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shown 72 h after transfection, with GFP siRNA as controls. (C) Western
blot showing the depletion of Ajuba by siRNA with three different
target sites.

we stained for a known marker involved in DNA repair, p53BP1,
which accumulates at sites of DNA damage early in the response.
We found that depletion of Ajuba led to a significant increase of
nuclei with more than five p53BP1 foci (Figures 3A,B), with 37%
of nuclei compared to 2% of nuclei in GFP control experiments. In
HTC75 cells, there is an average of two p53BP1 foci, which could be
detected in control siRNAs and represented a background level in
these cells. This apparent induction of the DDR in S phase likely
activated a known DNA repair pathway, and in particular ATR,
sensitive to DNA replication stress. Indeed, there was activation of
ATR following Ajuba depletion, as observed by phosphorylation
of Chk1 at residues Ser-345 and Ser-296, which are both ATRdependent (Liu et al., 2000; Okita et al., 2012) (Figure 3C). In
accordance with this finding, p53 was also weakly activated by
Ajuba depletion (Figure 3D), as observed by Ser20 phosphorylation associated with siRNA #3. It is possible that this effect is due
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FIGURE 2 | HTC75 cells depleted for Ajuba show S-phase delay. Attached
and floating cells were processed 72 h after siRNA transfection for (A) FACS
sorting after PI staining, and (B) Western blots for phosphorylated Rb or total

to activation of ATM as a subsequent effect, although we could
not detect perceptible Chk2 phosphorylation (not shown). In all
cases, the effects were again best seen with siRNA#3. Altogether,
these results support the conclusion that Ajuba depletion led to
phosphorylation of Chk1 and activation of p53, suggesting a role
for Ajuba in repressing the ATR pathway.
We then analyzed the possible activation of apoptosis following
Ajuba depletion by probing for PARP, which is cleaved by caspase
3 upon induction of apoptosis. We found extensive accumulation
of the PARP cleavage product upon Ajuba depletion, again most
significantly with siRNA #3 (Figure 4A). Concomitantly, the number of dead cells doubled for siRNAs #1 and 2, representing 18%
of the cell count, compared to 7% with the GFP siRNA control,
and topped 30% with siRNA #3 (Figure 4B).
We conclude that the cell death observed was due to the activation of the endogenous apoptotic pathway following ATR and p53
and activation.
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levels of Cyclin A2, with GAPDH as a loading control. (C) Cell cycle profiles of
cells processed as in (A), with% of cells in G1 or G2/M indicated as averages
of three independent experiments.

DEPLETION OF AJUBA IN IMR90 CELLS RESULTS IN A G2/M DELAY

It was important to analyze the response to Ajuba depletion in
another, unrelated cell line in order to establish the importance of
the results, and also to address whether the molecular events were
specific to tumor cells, or applicable to normal, non-transformed,
diploid cells. We chose for this purpose the cell line IMR90, a
commonly used primary human fibroblast line. We found that
the effects of Ajuba depletion were strikingly similar between
HTC75 and IMR90, and not acquired properties as part of a tumor
phenotype.
Depletion of Ajuba in IMR90 cells (Figure 6A) led to a reduction in cell count (Figures 5A,B) and an apparent delay in the
cell cycle (Figure 5C). In this case, the delay appeared to be
at the G2/M phase (averages of 22.79% against 9.23% in controls) (Figure 5C), corresponding to another known checkpoint
for ATR-Chk1 (through Cdc25C, see Discussion). In depleted
cells, an increase in Cyclin A2 (Figure 6C), phosphorylation of
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FIGURE 3 | Depletion of Ajuba results in activation of the DNA damage response. (A) Staining for p53BP1 foci on cells fixed 72 h after transfection with
siRNA #3, and siGFP as a negative control. Quantification of the number of p53BP1 foci on three independent siRNA experiments shown in (B). (C, D) Western
blots for induction of Chk1 phosphorylation and induction of p53 phosphorylation, showed for the three target sites, 72 h after siRNA transfection.

Chk1 (Figure 6D), and, to a lesser degree, hyperphosphorylation of Rb (Figure 6C), were observed, most prominently with
siRNA #3 (not shown). The induction of p53BP1 foci was also
evident in Ajuba-depleted cells (Figure 6B). We did detect a
low level of PARP cleavage indicating some degree of apoptosis in the cell population (Figure 6D), in accordance with what
we observed in HTC75 cells. However, massive apoptosis was
not observed nor expected, given the low degree of apoptosis activation in human fibroblasts (Duelli and Lazebnik, 2000).
Thus, the nature of the response was highly similar in both cell
types analyzed, with, in both cases, an obvious activation of ATR
signaling.

www.frontiersin.org

We conclude that depletion of Ajuba in IMR90 leads to a
qualitatively similar response to our tumor cell system HTC75,
which corresponds to ATR activation, but with a different outcome regarding the nature of the cell cycle profile (G2/M delay in
IMR90 versus S-phase delay in HTC75). This variation could be
due to the different downstream effects of ATR signaling in these
two different cell types.
AJUBA IS IN A COMPLEX WITH RPA IN UNPERTURBED HTC75 OR
IMR90 CELLS

In order to obtain insight on the role of Ajuba in early ATR activation, we reasoned that it could inhibit signaling in the absence

May 2013 | Volume 4 | Article 95 | 5

Kalan et al.

Ajuba represses ATR

FIGURE 4 | HTC75 cells depleted for Ajuba undergo apoptosis. (A) Western blot probed with anti-PARP antibody (top), with GAPDH as a loading control
(bottom), for the siRNAs indicated on top of the lanes. (B) Cell viability measured by Trypan Blue staining, 72 h after transfection with the indicated siRNAs.

of extensive DNA damage during the course of a normal S phase,
and that depletion of Ajuba might engage an inappropriately massive response to replication stress. One possibility of how Ajuba
exerts its influence on ATR signaling is suggested by our analysis of the role of another, related, LIM protein, TRIP6. We have
found that TRIP6 binds POT1 by associating with the OB folds
of the protein, and represses the DDR at telomeres (Sheppard
and Loayza, 2010). Given the high similarity between TRIP6 and
Ajuba, we hypothesized that the Ajuba LIM domains could be
dedicated to associate with the RPA OB folds, a known platform
for ATR activation (Xu et al., 2008). We tested this hypothesis
by asking whether we could immunoprecipitate RPA with Ajuba
antibodies (Figure 7A). We found that, in both HTC75 and IMR90
cells, RPA32 could be pulled down with a monoclonal anti-Ajuba
antibody as well as with an anti-Ajuba peptide serum, suggesting an interaction between the RPA complex and Ajuba in these
cells. Since RPA phosphorylation is required for ATR activation,
we hypothesized that Ajuba could prevent this modification. A
direct prediction of this model is that, in Ajuba-depleted cells, RPA
should be detected as a phosphorylated form indicating activation
of the early steps in the ATR pathway. We have tested a monoclonal
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antibody raised against phosphorylated RPA32-Thr21, known to
be PIKK-dependent (Anantha et al., 2007), and found that this
form of RPA was significantly increased in Ajuba-depleted cells
(Figure 7B). Again, this effect was observed in both cell types
used in this study. It would be interesting to test other RPA
phosphorylation sites (Liu et al., 2012), such as Ser33 (ATRdependent) or Ser4/8 (DNA-PK-dependent). We propose a model
(Figure 7C), based on our results, in which Ajuba, in unperturbed
cells, associates with RPA and protects RPA from unscheduled
phosphorylation events, which could lead to an inappropriate ATR
response.

DISCUSSION
This study describes the implication of a novel partner in the
DDR, the LIM protein Ajuba. We show here that Ajuba can be
described as an inhibitor of the ATR-dependent DDR. This conclusion is based on our observations that depletion of Ajuba leads
to a genome-wide DDR which is consistent with ATR activation,
such as Chk1 phosphorylation, p53 activation, and induction of
p53BP1 foci. The resulting response is a strong overall activation of the pathway as judged by the detection of PARP cleavage,
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FIGURE 5 | IMR90 cells depleted for Ajuba have reduced cell number
and a G2/M delay. (A) Cell counts of IMR90 cells taken 72 h after
transfection of siRNA #3. (B) Picture of IMR90 cells for siRNA #3 taken

indicating the induction of an apoptotic response. Since these
effects are observed in cells that are not experiencing exogenous
insults, such as UV irradiation or treatment with drugs inhibiting
DNA replication, we argue that Ajuba protects against an unscheduled and excessive response to endogenous DNA damage, which
we believe is likely to come from spontaneous replication stress.
These possible endogenous DNA damage signals could be the sites
of accumulation of p53BP1, possibly representing fork collapses,
misincorporated nucleotides, or intra or inter-strand crosslinks
for instance. Although our experiments do not address the type
of damage eliciting the response, we argue that this damage is
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72 h after transfection. (C) Cell cycle profiles of cells processed as in (B),
with% of cells in G2/M indicated as averages of three independent
experiments.

normally too weak to activate a full-blown DDR in the presence
of Ajuba, but, in Ajuba-depleted cells, can lead to an inappropriate
and unscheduled genome-wide response which is lethal to most
of the cells and leads to apoptosis. Our results are compatible with
other reports (Sørensen et al., 2003; Sorensen et al., 2004) that
found the ATR-Chk1-Cdc25A pathway being part of a “surveillance mode” during a normal S phase, but can be activated into an
“emergency” DDR after treatment with hydroxyurea, aphidicolin,
or UV for instance. We propose here that Ajuba is in this context
part of a system that keeps the ATR response in a “surveillance”
mode, which could be relieved after extensive exogenous DNA
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FIGURE 6 | IMR90 cells depleted for Ajuba undergo a DNA damage
response. (A,C,D) Western blots for Ajuba, Cyclin A, Rb, Chk1
phosphorylation, and PARP cleavage on lysates prepared from IMR90 cells

damage. Thus, Ajuba-depleted cells would respond with excessive
strength to endogenous and sporadic DNA replication lesions.
We hypothesized that Ajuba plays an important role in inhibiting the DDR mostly in cells of tumor origin due to rampant
genome instability and high chromosomal DNA damage in these
cells. We therefore analyzed the response in normal human diploid
fibroblasts to ask whether the role of Ajuba was important in a context of low level of endogenous DNA damage. Our results show
that indeed Ajuba is also important in non-tumor cells to repress
the ATR response in absence of exogenous DNA damage. In the
diploid fibroblasts we used, the cells responded by a delay in the cell
cycle and cell death as well. We observed a qualitative difference in
the nature of the cell cycle delay, which corresponded to a G2/M
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72 h after transfection with siRNA #3. The loading controls with GAPDH for
each blot are shown. (B) Staining for p53BP1 in Ajuba-depleted cells
(siRNA#3), with siGFP as a control.

delay in IMR90 cells compared with a S-phase delay in HTC75
cells. The difference in this aspect of the response could be due
to the intrinsic wiring of the ATR response in normal fibroblasts,
leading to a robust inhibition of Cdc25C and delay of entry into
mitosis in these cells. Tumor cells, however, could experience an
effect mostly on Cdc25A, which is degraded after Chk1 activation
(for review, see Zhou and Bartek, 2004). Degradation of Cdc25A
has multiple effects in various parts of the cell cycle, one of them
being a strong delay in S phase. More work is required to establish
which of Cdc25A or Cdc25C is mostly impacting the cell cycle
profiles in either cell types, as well as in other cell types. We think
it plausible, although not addressed here, that in both cases the
signaling is initiated in S phase in response to DNA replication
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FIGURE 7 | Ajuba associates with RPA in HTC75 and IMR90 cells. (A)
IP-Western probed with a total anti-RPA32 antibody after immunoprecipitation
with a commercial anti-Ajuba antibody (com.) or anti-peptide serum from
IMR90 or HTC75 extracts as indicated. Left panel: total lysates (input) for each
cell line, and the pre-immune serum (PI) used as a control for the

stress. Thus, the role of Ajuba appears to be important in the context of a normal S phase. In both cell types analyzed here, the
response observed is so extensive as to lead to cell death and apoptosis, particularly in the case of the HTC75 cells. Also, this aspect
of the response, including activation of p53 and cleavage of PARP,
could be under dependence of ATM, known to be activated by a
sustained ATR response, and not necessarily a direct effect of the
ATR-Chk1 pathway. Such effects have been noted by others (see
Hurley and Bunz, 2007).
Overall, these observations imply that ATR is poised for a
full-blown response to DNA damage and the pathway requires
repression, exerted in part by Ajuba, for progression through the
cell cycle, which would allow for local ATR activation at sporadic
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immunoprecipitation. (B) Western for RPA32-p-Thr21 in both HTC75 and
IMR90Ajuba-depleted cells. A non-specific band is marked by a *. Total RPA32
levels are shown at the bottom. (C) Model for the role of Ajuba in repression
of ATR. The “?” indicates that the interaction between Ajuba and RPA could
be direct or indirect. See text for details.

sites of replication stress such as replication fork collapse or excessive production of single stranded DNA, for instance. Repressors
such as Ajuba would keep the response localized and allow for
rapid repair and continuation of S phase.
Following the observations linking Ajuba to the repression
of the ATR response, we sought to determine the mechanism
of action of Ajuba in the ATR activation pathway. We focused
on RPA, an essential single strand DNA binding protein constituted by three OB-fold-containing subunits, RPA70, RPA32,
and RPA14. RPA has long been documented as playing essential roles in DNA replication, DNA repair and recombination
(Wold, 1997), and is an early player in ATR activation following DNA damage (Zou and Elledge, 2003). RPA70 constitutes a
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platform for the binding of a number of proteins essential for
ATR activation, through direct contacts with ATRIP and RAD9,
and further recruiting ATR and TOPBP1 (Xu et al., 2008). It is
tempting to speculate that Ajuba could bind RPA and prevent
ATR activation in undamaged or unstressed cells, thereby preventing the formation of ATR-activating foci. In addition, our
laboratory has discovered a similar interaction between POT1,
the telomeric overhang binding protein, and the LIM protein
TRIP6 (Sheppard and Loayza, 2010). This interaction was initially discovered through a yeast two-hybrid screen, and involved
the POT1 N-terminal OB folds and the C-terminal LIM domains
of TRIP6. We hypothesized that this domain interaction could be
conserved in other protein partners, and in particular between
OB-fold-containing RPA and LIM-containing Ajuba. Our results
indeed support this hypothesis since RPA could be found in
a complex with Ajuba. We are currently following up on this
result in asking whether there is a direct interaction between
the OB-folds found in RPA and Ajuba in a recombinant protein system. A clear prediction of our model of RPA shielding
by Ajuba (Figure 7C) is that, in Ajuba-depleted cells, we should
observe increased RPA32 phosphorylation, an early step in ATR
activation. Supporting this model, we could clearly detect such
an event by looking at RPA32-Thr21 phosphorylation, but more
work is required to dissect the exact role of Ajuba in this process.
Indeed, the phosphorylation of RPA32 displays a complex pattern, with Thr21 being dependent on ATR itself, Ser33 on ATM
and believed to occur during a sustained response, and Ser4 and
Ser8 believed to be essential for the early phase of the induction, perhaps even before activation of ATR itself, with DNA-PK
as an effector kinase (Liu et al., 2012). Our results show that

Ajuba protects from unscheduled Thr21 phosphorylation, definitely placing this molecule at the level of RPA in the repression
of the ATR response. Our working model given our results is that
Ajuba interacts with the RPA complex and prevents inappropriate
phosphorylation of RPA32. It will be interesting to address in the
future whether such a role is restricted to S phase or important
throughout the cell cycle. Also, whether Ajuba prevents DNA-PKdependent, or ATR-dependent phosphorylation, or both, remains
to be established.
This leaves an important question: how can ATR be activated
in the course of DNA replication stress or DNA damage? Possibly,
free RPA exists in the cell that could get phosphorylated following such lesions, modifications that could significantly reduce the
binding affinity for Ajuba and generate a free, unbound pool able
to generate a local ATR response, or a more sustained one depending on the extent of the damage. We are currently testing with
recombinant proteins whether the interactions between Ajuba and
RPA are direct, and whether specific phosphorylation sites reduce
the binding affinities of these interactions, as we would predict. A
broader impact of Ajuba and related molecules is that they could
have oncogenic properties during early events of cellular transformation by inhibiting the protective or tumor suppressive effects
of ATR.

REFERENCES

Loayza, D., and de Lange, T. (2003).
POT1 as a terminal transducer
of TRF1 telomere length control.
Nature 424, 1013–1018.
Okita, N., Minato, S., Ohmi, E., Tanuma,
S., and Higami, Y. (2012). DNA
damage-induced CHK1 autophosphorylation at Ser296 is regulated by
an intramolecular mechanism. FEBS
Lett. 586, 3974–3979.
Palm, W., and de Lange, T. (2008).
How shelterin protects mammalian
telomeres. Annu. Rev. Genet. 42,
301–334.
Palm, W., Hockemeyer, D., Kibe, T., and
de Lange, T. (2009). Functional dissection of human and mouse POT1
proteins. Mol. Cell. Biol. 29, 471–482.
Sheppard, S. A., and Loayza, D. (2010).
LIM-domain proteins TRIP6 and
LPP associate with shelterin to
mediate telomere protection. Aging
(Albany N.Y.) 2, 432–444.
Sheppard, S. A., Savinova, T., and
Loayza, D. (2011). TRIP6 and LPP,
but not Zyxin, are present at a subset of telomeres in human cells. Cell
Cycle 10, 1–5.
Sørensen, C. S., Syljuåsen, R. G.,
Falck, J., Schroeder, T., Rönnstrand,
L., Khanna, K. K., et al. (2003).

Anantha, R. W., Vassin, V. M., and
Borowiec, J. A. (2007). Sequential and synergistic modification of
human RPA stimulates chromosomal DNA repair. J. Biol. Chem. 282,
35910–35923.
Bartkova, J., Horejsí, Z., Koed, K.,
Krämer, A., Tort, F., Zieger, K., et al.
(2005). DNA damage as a candidate
anti-cancer barrier in early human
tumorigenesis. Nature 434, 864–870.
Ciccia, A., and Elledge, S. J. (2010). The
DNA damage response: making it
safe to play with knives. Mol. Cell 40,
179–204.
Duelli, D. M., and Lazebnik,Y. A. (2000).
Primary cells suppress oncogenedependent apoptosis. Nat. Cell Biol.
2, 859–862.
Gorgoulis, V. G., Vassiliou, L. V.,
Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., et al. (2005).
Activation of the DNA damage
checkpoint and genomic instability in human precancerous lesions.
Nature 434, 907–913.
Hurley, P. J., and Bunz, F. (2007).
ATM and ATR: components of
an integrated circuit. Cell Cycle 6,
414–417.

Kadrmas, J. L., and Beckerle, M. C.
(2004). The LIM domain: from the
cytoskeleton to the nucleus. Nat. Rev.
Mol. Cell Biol. 5, 920–931.
Karlseder, J., Hoke, K., Mirzoeva,
O. K., Bakkenist, C., Kastan, M.
B., Petrini, J. H., et al. (2004).
The telomeric protein TRF2 binds
the ATM kinase and can inhibit
the ATM-dependent DNA damage response. PLoS Biol. 2:E240.
doi:10.1371/journal.pbio.0020240
Lazzerini Denchi, E., and de Lange,
T. (2007). Protection of telomeres through independent control of
ATM and ATR by TRF2 and POT1.
Nature 448, 1068–1071.
Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., et al.
(2000). Chk1 is an essential kinase
that is regulated by Atr and required
for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448–1459.
Liu, S., Opiyo, S. O., Manthey, K.,
Glanzer, J. G., Ashley, A. K., Amerin,
C., et al. (2012). Distinct roles
for DNA-PK, ATM and ATR in
RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res. 40,
10780–10794.

Frontiers in Genetics | Cancer Genetics

ACKNOWLEDGMENTS
The authors thank the Diego Loayza laboratory for help, advice,
and comments on the manuscript, the Foster laboratory for technical advice, and P. Maguin for excellent technical support. This
work was funded by a SC3 award # 1SC3GM094071-01A1 from
the NIGMS.

Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiationinduced accelerated proteolysis of
Cdc25A. Cancer Cell 3, 247–258.
Sorensen, C. S., Syljuasen, R. G., Lukas,
J., and Bartek, J. (2004). ATR, Claspin
and the Rad9-Rad1-Hus1 complex
regulate Chk1 and Cdc25A in the
absence of DNA damage. Cell Cycle
3, 941–945.
van Steensel, B., and de Lange, T.
(1997). Control of telomere length
by the human telomeric protein
TRF1. Nature 385, 740–743.
Vassin, V. M., Anantha, R. W., Sokolova,
E., Kanner, S., and Borowiec, J.
A. (2009). Human RPA phosphorylation by ATR stimulates
DNA synthesis and prevents
ssDNA accumulation during DNAreplication stress. J. Cell. Sci. 122,
4070–4080.
Wang, Y., and Gilmore, T. D. (2001).
LIM domain protein Trip6 has a conserved nuclear export signal, nuclear
targeting sequences, and multiple
transactivation domains. Biochim.
Biophys. Acta 1538, 260–272.
Wold, M. S. (1997). Replication protein
A: a heterotrimeric, single-stranded

May 2013 | Volume 4 | Article 95 | 10

Kalan et al.

DNA-binding protein required for
eukaryotic DNA metabolism. Annu.
Rev. Biochem. 66, 61–92.
Xu, X., Vaithiyalingam, S., Glick, G. G.,
Mordes, D. A., Chazin, W. J., and
Cortez, D. (2008). The basic cleft of
RPA70N binds multiple checkpoint
proteins, including RAD9, to regulate ATR signaling. Mol. Cell. Biol. 28,
7345–7353.
Zhou, B. B., and Bartek, J. (2004).
Targeting the checkpoint kinases:

www.frontiersin.org

Ajuba represses ATR

chemosensitization versus chemoprotection. Nat. Rev. Cancer 4,
216–225.
Zou, L., and Elledge, S. J. (2003). Sensing
DNA damage through ATRIP recognition of RPA-ssDNA complexes.
Science 300, 1542–1548.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any commercial or financial relationships that

could be construed as a potential conflict of interest.
Received: 29 March 2013; accepted: 07
May 2013; published online: 28 May
2013.
Citation: Kalan S, Matveyenko A
and Loayza D (2013) LIM protein Ajuba participates in the repression of the ATR-mediated DNA damage response. Front. Genet. 4:95. doi:
10.3389/fgene.2013.00095

This article was submitted to Frontiers in
Cancer Genetics, a specialty of Frontiers
in Genetics.
Copyright © 2013 Kalan, Matveyenko
and Loayza. This is an open-access article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are credited and subject to any copyright notices
concerning any third-party graphics etc.

May 2013 | Volume 4 | Article 95 | 11

